POC(Point of Care) 약물남용 검사 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 샘플 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Point Of Care Drug Of Abuse Testing Market Summary

The global point of care drug of abuse testing market size was estimated at USD 1.08 billion in 2024 and is projected to reach USD 2.45 billion by 2033, growing at a CAGR of 9.62% from 2025 to 2033, due to increasing substance misuse worldwide and the urgent need for rapid, decentralized drug testing solutions. POC testing, which includes urine, saliva, breath, and sweat-based kits, provides rapid results at the site of sample collection, eliminating the need for complex lab infrastructure.

These tools are increasingly being adopted in clinical settings, roadside enforcement, schools, and even at home, making them a key component in public health and safety strategies globally. Technological advancements are significantly enhancing the accuracy, speed, and usability of POC DOA testing devices. The development of immunoassay-based test strips, portable analyzers, and digital readers enables fast results with minimal sample handling. AI and machine learning are beginning to integrate into some testing platforms, assisting in result interpretation and reducing operator error. Non-invasive sampling methods, such as oral fluid and sweat-based testing, are improving user compliance and privacy. In addition, newer devices now support multi-panel drug testing, enabling simultaneous detection of multiple substances such as opioids, cannabis, cocaine, amphetamines, and benzodiazepines. These innovations are crucial in settings where quick decision-making is essential-such as emergency departments, law enforcement operations, and rehabilitation centers. The miniaturization of diagnostic technology and improved connectivity features, including smartphone integration and Bluetooth-enabled data logging, are making these tools more accessible and user-friendly, driving adoption in both professional and consumer markets.

Government regulations and workplace safety initiatives are key drivers in the expansion of the POC DOA testing market. In countries such as the U.S., federal mandates require drug screening for safety-sensitive industries such as transportation, aviation, and healthcare. This has led to widespread use of on-site testing kits that provide rapid screening without needing laboratory confirmation unless a positive result arises. Roadside drug testing programs, particularly in jurisdictions with legalized cannabis use, are also boosting demand for accurate and mobile POC devices. Moreover, school drug prevention programs and military recruitment processes increasingly incorporate quick screening methods to deter and identify drug use early. In Europe and parts of Asia, evolving workplace safety laws and anti-doping initiatives are supporting broader implementation. These frameworks not only promote public safety but also create a steady demand for reliable, cost-effective, and easy-to-use testing solutions that can be deployed in a range of decentralized environments.

The growing demand for privacy, convenience, and self-monitoring has led to a significant rise in at-home DOA testing. These kits allow individuals to test themselves or others in private settings using saliva, urine, or hair samples. The COVID-19 pandemic further accelerated the adoption of self-testing models, as consumers and healthcare providers looked for ways to monitor health remotely. Telehealth services have incorporated these kits for patients undergoing addiction treatment or pain management, enhancing continuity of care.

Global Point of Care Drug of Abuse Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point of care drug of abuse testing market based on product, technology, sample type, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Immunoassay Test Strips and Cassettes
• Oral Fluid Testing Kits
• Breath Analyzers
• Urine Collection Cups
• Digital/Portable Analyzers
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Lateral Flow Assay (LFA)
• Chromatographic Immunoassays
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Mass Spectrometry (portable or hybrid POC units)
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Emergency Departments
• Workplace & Occupational Health Center
• Home Care & Remote Users
• Others
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Urine
• Saliva (Oral Fluid)
• Breath
• Blood
• Sweat/Hair
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Point of Care Drug of Abuse (DOA) Testing Market: Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. Test Type segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Point of Care Drug of Abuse (DOA) Testing Market: Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Application Snapshot
• 2.3. Test Type Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Point of Care Drug of Abuse (DOA) Testing Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers Analysis
  • 3.4.1. Rising Substance Abuse Rates
  • 3.4.2. Technological Advancements in Testing Devices
  • 3.4.3. Growing Preference for Decentralized Testing
• 3.5. Market Restraint Analysis
  • 3.5.1. Risk of False Positives/Negatives
  • 3.5.2. Regulatory and Reimbursement Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis
• 3.8. Pipeline Analysis

Chapter 4. Point of Care Drug of Abuse (DOA) Testing Market: Product Estimates & Trend Analysis

• 4.1. Point of Care Drug of Abuse (DOA) Testing Market: Product Movement Analysis
• 4.2. Immunoassay Test Strips and Cassettes
• 4.3. Oral Fluid Testing Kits
  • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Breath Analyzers
  • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Urine Collection Cups
  • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Digital/Portable Analyzers
  • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Estimates & Trend Analysis

• 5.1. Point of Care Drug of Abuse (DOA) Testing Market: Sample Type Movement Analysis
• 5.2. Urine
  • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.3. Saliva (Oral Fluid)
  • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Breath
  • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Blood
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Sweat/Hair
  • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point of Care Drug of Abuse (DOA) Testing Market: Technology Estimates & Trend Analysis

• 6.1. Point of Care Drug of Abuse (DOA) Testing Market: Technology Movement Analysis
• 6.2. Lateral Flow Assay (LFA)
  • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.3. Chromatographic Immunoassays
  • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Enzyme-Linked Immunosorbent Assay (ELISA)
  • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Mass Spectrometry (portable or hybrid POC units)
  • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point of Care Drug of Abuse (DOA) Testing Market: End Use Estimates & Trend Analysis

• 7.1. Point of Care Drug of Abuse (DOA) Testing Market: End Use Movement Analysis
• 7.2. Hospitals & Emergency Departments
  • 7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Workplace & Occupational Health Center
  • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Home Care & Remote Users
  • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Others
  • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point of Care Drug of Abuse (DOA) Testing Market: Regional Business Analysis

• 8.1. Regional Market Snapshot
• 8.2. North America
  • 8.2.1. North America Point of Care Drug of Abuse (DOA) Testing Market Estimates And Forecast, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.2.2.2. Key Country Dynamics
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Reimbursement Scenario
    • 8.2.2.5. Competitive Scenario
  • 8.2.3. Canada
    • 8.2.3.1. Canada Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.2.3.2. Key Country Dynamics
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Reimbursement Scenario
    • 8.2.3.5. Competitive Scenario
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.2.4.2. Key Country Dynamics
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Reimbursement Scenario
    • 8.2.4.5. Competitive Scenario
• 8.3. Europe
  • 8.3.1. Europe Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.2.2. Key Country Dynamics
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Reimbursement Scenario
    • 8.3.2.5. Competitive Scenario
  • 8.3.3. Germnay
    • 8.3.3.1. Germany Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.3.2. Key Country Dynamics
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Reimbursement Scenario
    • 8.3.3.5. Competitive Scenario
  • 8.3.4. Spain
    • 8.3.4.1. Spain Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.4.2. Key Country Dynamics
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Reimbursement Scenario
    • 8.3.4.5. Competitive Scenario
  • 8.3.5. France
    • 8.3.5.1. France Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.5.2. Key Country Dynamics
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Reimbursement Scenario
    • 8.3.5.5. Competitive Scenario
  • 8.3.6. Italy
    • 8.3.6.1. Italy Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.6.2. Key Country Dynamics
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Reimbursement Scenario
    • 8.3.6.5. Competitive Scenario
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.7.2. Key Country Dynamics
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Reimbursement Scenario
    • 8.3.7.5. Competitive Scenario
  • 8.3.8. Sweden
    • 8.3.8.1. Sweden Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.8.2. Key Country Dynamics
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Reimbursement Scenario
    • 8.3.8.5. Competitive Scenario
  • 8.3.9. Norway
    • 8.3.9.1. Norway Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.3.9.2. Key Country Dynamics
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Reimbursement Scenario
    • 8.3.9.5. Competitive Scenario
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Japan Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.2.2. Key Country Dynamics
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Scenario
    • 8.4.2.5. Competitive Scenario
  • 8.4.3. China
    • 8.4.3.1. China Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.3.2. Key Country Dynamics
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Scenario
    • 8.4.3.5. Competitive Scenario
  • 8.4.4. India
    • 8.4.4.1. India Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.4.2. Key Country Dynamics
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Scenario
    • 8.4.4.5. Competitive Scenario
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.5.2. Key Country Dynamics
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Reimbursement Scenario
    • 8.4.5.5. Competitive Scenario
  • 8.4.6. Thailand
    • 8.4.6.1. Thailand Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.6.2. Key Country Dynamics
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Reimbursement Scenario
    • 8.4.6.5. Competitive Scenario
  • 8.4.7. Australia
    • 8.4.7.1. Australia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.4.7.2. Key Country Dynamics
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Reimbursement Scenario
    • 8.4.7.5. Competitive Scenario
• 8.5. Latin America
  • 8.5.1. Latin America Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.5.2.2. Key Country Dynamics
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Scenario
    • 8.5.2.5. Competitive Scenario
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.5.3.2. Key Country Dynamics
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Scenario
    • 8.5.3.5. Competitive Scenario
• 8.6. MEA
  • 8.6.1. MEA Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. South Africa Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.2.2. Key Country Dynamics
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Scenario
    • 8.6.2.5. Competitive Scenario
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Saudi Arabia Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.3.2. Key Country Dynamics
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Scenario
    • 8.6.3.5. Competitive Scenario
  • 8.6.4. UAE
    • 8.6.4.1. UAE Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.4.2. Key Country Dynamics
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Scenario
    • 8.6.4.5. Competitive Scenario
  • 8.6.5. Kuwait
    • 8.6.5.1. Kuwait Point of Care Drug of Abuse (DOA) Testing Market, 2021 - 2033 (USD Million)
    • 8.6.5.2. Key Country Dynamics
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Scenario
    • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
  • 9.2.1. NEW PRODUCT LAUNCH
  • 9.2.2. PARTNERSHIPS
  • 9.2.3. ACQUISITION
  • 9.2.4. COLLABORATION
  • 9.2.5. FUNDING
• 9.3. Key Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis
• 9.5. Company Profiles
  • 9.5.1. ABBOTT
    • 9.5.1.1. Company Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. QUEST DIAGNOSTICS
    • 9.5.2.1. Company Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. THERMO FISHER SCIENTIFIC
    • 9.5.3.1. Company Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. ORASURE TECHNOLOGIES
    • 9.5.4.1. Company Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. SIEMENS HEALTHINEERS
    • 9.5.5.1. Company Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. F. HOFFMANN-LA ROCHE LTD.
    • 9.5.6.1. Company Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Dragerwerk AG & Co. KGaA
    • 9.5.7.1. Company Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. LABCORP (LABORATORY CORPORATION OF AMERICA HOLDINGS)
    • 9.5.8.1. Company Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. PREMIER BIOTECH, INC.
    • 9.5.9.1. Company Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives